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Galectin-1: A Potential Protein Therapy
for Limb-Girdle Muscular Dystrophy 2B
Mary L Vallecillo1, Matthew S Teynor1, Jonard C Valdoz1, Spencer D Hayes1, P. Daniel Poulson1, Matthew F Rathgeber1, Sean R Stowell2, and Pam M Van Ry1
1Department of Chemistry & Biochemistry, Brigham Young University, Provo, Utah
2Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia

• Limb-Girdle Muscular Dystrophy 2B (LGMD2B) belongs to a group of
diseases called dysferlinopathies, caused by mutations in the DYSF gene.
• Dysferlin is an important muscle membrane protein involved in repair and
regeneration after injury.
• LGMD2B causes muscle wasting, fat infiltration, and loss of ambulation in
patients.
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0.014μM to 0.22μM, were
stained and the fusion
index was calculated. For
every dose, cells treated
with rHsGal-1 had average
fusion indexes similar to
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• Currently there is no cure and few treatment options.
• Galectin-1 is a small protein that interacts with glycosylated proteins. It
shows efficacy in treating murine models of Duchenne Muscular Dystrophy.
• Here we explore the ability of recombinant human Galectin-1 (rHsGal-1) to
ameliorate disease pathologies and mechanisms of LGMD2B

Hypothesis
Possible Roles for Galectin-1 Protein Therapy in LGMD2B

rHsGal-1 increases cell migration and wound healing. We performed a wound healing assay
using inserts that allowed cells to grow into a simulated wound after the inserts were removed. We
saw that myoblasts treated with rHsGal-1 closed faster and more completely than NT myoblasts. Of
particular interest, it qualitatively appears that cells treated with rHsGal-1 form myotubes in the
wound area during the 48hrs after the inserts were removed, while non-treated cells do not. This
helps to confirm previous results that indaicate rHsGal-1 can increased fusion and maturation of
myoblasts to myotubes. Likewise, it shows that rHsGal-1 can increase migratory factors, which are
linked to better in vivo muscle repair.
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rHsGal-1 increases myotube
formation and fusion index.
A/J-/- myotubes treated with
0.11µM rHsGal-1 had increased
fusion index (fraction of nuclei
incorporated into myotubes) and
dramatically increased average
nuclei per myotube compared to
WT and NT.

Hypothesis: Recombinant human galectin-1 (rHsGal-1) protein treatment will
improve membrane repair of LGMD2B models thus increasing myogenesis, stabilizing
muscle integrity, and decreasing disease manifestation.

Results

Increased Membrane Repair

rHsGal-1 increases myogenic potential
regulatory factors and myotube formation.
To further investigate changes in myogenic
potential, we measured levels of early, mid, and late
myogenic regulatory factors (Pax7, MyoD, and
MHC, respectively). At the 0.11μM rHsGal-1
treatment level, we saw a 1.35 fold decrease in Pax7
protein expression, and 2.5 and 1.24 fold increases
in MyoD and MHC protein expression, respectively.
These data indicate that rHsGal-1 increase
myogenic potential by pushing myoblasts towards
late stages of myogenesis. We also saw large
increases in both Galectin-1 and His-tag levels with
0.11μM rHsGal-1 treatment, as would be expected.

0.11µM rHsGal-1

0.11µM rHsGal-1 is the optimal dose for
increasing myogenin expression. Non-treated
A/J-/- cells (NT) and A/J-/- cells treated with rHsGal-1,
with doses ranging from 0.054μM to 0.22μM, were
analyzed using anti-myogenin antibody to determine
the optimal dose of rHsGal-1 needed to increase
myogenesis. We saw a 1.96 fold increase in myogenin,
a transcription factor associated with late stages of
myogenesis, expression at a dose of 0.11μM rHsGal-1
compared to NT.

A/J-/- myotubes and myofibers treated with rHsGal-1 have increased membrane repair
capacity. Treated and non-treated A/J-/- myotubes were injured by a UV laser in the presence of FM1-43
dye and the membrane repair capacity was quantified by measuring the change in fluorescent intensity
inside the myotube after injury. Example images above qualitatively show that NT myotubes allow more dye
to enter than 0.11µM rHsGal-1 treated myotubes, indicating that treated myotubes have an increased
membrane repair capacity. Quantification of this data confirmed that treated myotubes had significantly
less dye entry after injury than NT.
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rHsGal-1 decreased levels of
NFκB subunits in A/J-/- cells.
Immunofluorescent images of A/J-/cells show decreases in p65
expression for treated cells. Western
blot analysis of p50, p65, and p105
all show decreasing levels as
duration of treatment increases.

rHsGal-1 treatment leads to increased levels of
LGALS1 transcript in A/J-/- cells. Real-time RT-QPCR
showed that treated cells had a 2-fold increase in LGALS1
transcript levels compared to both WT and NT. This shows that
rHsGal-1 starts a positive feedback loop, which induces the
transcription of endogenous Galectin-1.
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The cDNA encoding for LGALS1
was cloned into the pET29B (+)
vector and over expressed in
BL21(DE3) competent E. coli
cells. The purity of galectin-1 was
analyzed using western blot with
anti-Galectin-1 and anti-His.
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Conclusions
• rHsGal-1 increases myogenic regulatory factors and myotube formation.
• A/J-/- myotubes treated with rHsGal-1 have increased membrane repair

capacity.
• The CRD of galectin-1 is responsible for increased membrane repair in

dysferlin deficient myotubes.
•Wound healing in accelerated with rHsGal-1 treatment.
• Galectin-1 transcript levels are up regulated with rHsGal-1 treatment.
• NFκ-B pathway is downregulated with rHsGal-1 treatment in a time sensitive

manner.

rHsGal-1 mediated membrane repair is independent of myogenic improvements,
dependent on the CRD, and calcium independent. We also performed the laser injury assay using
different treatment times of rHsGal-1. An improvement after 10min of treatment indicates that the repair
mechanism is independent of myogenesis. Likewise, we found that lactose was able to inhibit the effects
of rHsGal-1. Because lactose binds to the CRD, we conclude that the CRD is vital to the function of Gal-1
in membrane repair. We also performed the same laser ablation assay in the presence of a calcium
chelators, EGTA and BAPTA-AM. We saw that calcium chelation impaired the membrane repair capacity
of NT myotubes, but did not affect the membrane repair capacity of treated myotubes. From this we
conclude that rHsGal-1 is able to increase the membrane repair capacity of A/J-/- myotubes independent
of an influx of extracellular calcium post injury, which canonically is the signal for membrane repair.
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